# enGene Therapeutics (ENGN) — Analyst Forecast

ENGN · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/engn/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Hold | 4 | 5 | 1 | 10 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Sep 9, 2026 | Citizens | Maintained | Market Perform | — |
| Sep 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $4.00 |
| Jun 18, 2026 | Morgan Stanley | Downgraded | Equal-Weight → Underweight | — |
| Jun 16, 2026 | HC Wainwright & Co. | Maintained | Buy | $4.00 |
| May 14, 2026 | UBS | Maintained | Neutral | $2.00 |
| May 8, 2026 | Piper Sandler | Downgraded | Overweight → Neutral | $4.00 |
| May 8, 2026 | HC Wainwright & Co. | Maintained | Buy | $6.00 |
| May 8, 2026 | Wells Fargo | Downgraded | Overweight → Equal-Weight | $2.00 |
| May 8, 2026 | Guggenheim | Downgraded | Buy → Neutral | — |
| May 8, 2026 | Citizens | Downgraded | Market Outperform → Market Perform | — |
| Apr 13, 2026 | WBB Securities | Initiated Coverage | Buy | $21.50 |
| Mar 11, 2026 | Oppenheimer | Maintained | Outperform | $30.00 |
| Mar 9, 2026 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Nov 12, 2025 | UBS | Maintained | Neutral | $10.00 |
| Nov 12, 2025 | Oppenheimer | Maintained | Outperform | $33.00 |
| Nov 12, 2025 | Morgan Stanley | Maintained | Overweight | $19.00 |
| Nov 12, 2025 | Citizens | Maintained | Market Outperform | $21.00 |
| Sep 12, 2025 | HC Wainwright & Co. | Maintained | Buy | $25.00 |
| Sep 12, 2025 | Morgan Stanley | Maintained | Overweight | $18.00 |
| Sep 8, 2025 | HC Wainwright & Co. | Maintained | Buy | $25.00 |

## Frequently Asked Questions

### Is ENGN a buy, sell, or hold?

Analysts covering enGene Therapeutics currently average a Hold rating: 4 buy, 5 hold and 1 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on ENGN?

On Sep 9, 2026, Citizens maintained enGene Therapeutics at Market Perform.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).